|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
US20230365563A1
(en)
*
|
2020-09-30 |
2023-11-16 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Quinazoline compound and application thereof
|
|
CN115181106B
(zh)
*
|
2021-04-07 |
2024-04-05 |
药雅科技(上海)有限公司 |
喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用
|
|
JP2024517695A
(ja)
*
|
2021-04-29 |
2024-04-23 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
WO2023278600A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Dana-Farber Cancer Institute, Inc. |
Small molecule inhibitors of kras g12d mutant
|
|
WO2023114733A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
MX2024008849A
(es)
|
2022-01-21 |
2024-07-25 |
Usynova Pharmaceuticals Ltd |
Compuestos de benzopirimidina y uso de estos.
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
AU2023218370B2
(en)
|
2022-02-09 |
2024-11-28 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN118344386A
(zh)
*
|
2023-01-13 |
2024-07-16 |
苏州泽璟生物制药股份有限公司 |
取代桥环类抑制剂及其制备方法和应用
|
|
IL317601A
(en)
|
2022-05-25 |
2025-02-01 |
Quanta Therapeutics Inc |
Pyrimidine-based modulators and their uses
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202416976A
(zh)
*
|
2022-09-16 |
2024-05-01 |
大陸商南京明德新藥研發有限公司 |
含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物
|
|
WO2024061365A1
(zh)
*
|
2022-09-22 |
2024-03-28 |
成都奥睿药业有限公司 |
嘧啶并环类化合物及其制备方法与用途
|
|
AU2023349002A1
(en)
*
|
2022-09-30 |
2025-05-15 |
Trasveda Ltd. |
Compounds with anti-kras mutant tumor activity
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
JP2025536369A
(ja)
|
2022-10-21 |
2025-11-05 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
|
|
CN117263959A
(zh)
*
|
2022-10-24 |
2023-12-22 |
药雅科技(上海)有限公司 |
芳香类kras突变蛋白抑制剂的制备及其应用
|
|
WO2024092420A1
(zh)
*
|
2022-10-31 |
2024-05-10 |
上海皓元医药股份有限公司 |
一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
WO2024186680A1
(en)
*
|
2023-03-03 |
2024-09-12 |
Frontier Medicines Corporation |
Methods for preparing pyrrolizidine compounds
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
WO2024215862A2
(en)
*
|
2023-04-12 |
2024-10-17 |
Board Of Regents, The University Of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
CN121419984A
(zh)
*
|
2023-04-26 |
2026-01-27 |
珃诺生物医药科技(杭州)有限公司 |
Kras（g12d）的二氮杂双环辛烷抑制剂及用途
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024230707A1
(zh)
*
|
2023-05-07 |
2024-11-14 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250114339A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
|
|
AU2024357850A1
(en)
|
2023-10-09 |
2026-04-23 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
KR102738924B1
(ko)
*
|
2023-12-26 |
2024-12-06 |
주식회사 베노바이오 |
Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|